US2003059934A1PendingUtilityA1

Artificial chromosomes comprising EHV sequences

50
Priority: Apr 3, 2001Filed: Mar 25, 2002Published: Mar 27, 2003
Est. expiryApr 3, 2021(expired)· nominal 20-yr term from priority
Inventors:Nikolaus OsterriederJens Rudolph
C12N 15/86A61K 2039/5256C12N 7/00C12N 2710/16661C12N 2710/16743C12N 2710/16761C12N 2800/204
50
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention belongs to the field of animal health, in particular equine diseases caused by equine herpesvirus (EHV). The invention relates to artificial chromosomes comprising the genome of equine herpesviruses, methods of producing attenuated or virulent EHV with or without the insertion of foreign genes, EHV obtainable with said methods and pharmaceutical compositions comprising said viruses.

Claims

exact text as granted — not AI-modified
What is claimed is:  
     
         1 . Bacterial artificial chromosome vector characterized in that it comprises essentially the entire genome of an EHV strain.  
     
     
         2 . The artificial chromosome vector according to  claim 1 , characterized in that the EHV is EHV-1.  
     
     
         3 . The artificial chromosome vector according to  claim 1 , characterized in that the EHV is EHV-4.  
     
     
         4 . The artificial chromosome vector according to  claim 1 , characterized in that the EHV strain is RacH.  
     
     
         5 . The artificial chromosome vector according to  claim 4 , chraterized in that it is the vector with the accession No. ECACC 01032704.  
     
     
         6 . The artificial chromosome vector according to  claim 1 , characterized in that the EHV strain is lacking the glycoprotein gB.  
     
     
         7 . The artificial chromosome vector according to  claim 1 , characterized in that the EHV strain is lacking the glycoprotein gC.  
     
     
         8 . The artificial chromosome vector according to  claim 1 , characterized in that the EHV strain is lacking the glycoprotein gD.  
     
     
         9 . The artificial chromosome vector according to  claim 1 , characterized in that the EHV strain is lacking the glycoprotein gE.  
     
     
         10 . The artificial chromosome vector according to  claim 1 , characterized in that the EHV strain is lacking the glycoprotein gG.  
     
     
         11 . The artificial chromosome vector according to  claim 1 , characterized in that the EHV strain is lacking the glycoprotein gH.  
     
     
         12 . The artificial chromosome vector according to  claim 1 , characterized in that the EHV strain is lacking the glycoprotein gI.  
     
     
         13 . The artificial chromosome vector according to  claim 1 , characterized in that the EHV strain is lacking the glycoprotein gK.  
     
     
         14 . The artificial chromosome vector according to  claim 1 , characterized in that the EHV strain is lacking the glycoprotein gL.  
     
     
         15 . The artificial chromosome vector according to  claim 1 , characterized in that the EHV strain is lacking the glycoprotein gM.  
     
     
         16 . The artificial chromosome vector according to  claim 1 , characterized in that the EHV strain is lacking the glycoprotein gp1/2.  
     
     
         17 . A polynucleotide encoding an artificial chromosome vector, which vector is characterized in that it comprises essentially the entire genome of an EHV strain, or EHV contained in the vector.  
     
     
         18 . A method for generating infectious EHV which comprises using an artificial chromosome vector, which vector is characterized in that it comprises essentially the entire genome of an EHV strain.  
     
     
         19 . A method for generating infectious EHV which comprises using the polynucleotide as according to  claim 18 .  
     
     
         20 . A method for generating EHV which comprises infecting a suitable cell line with the artificial chromosome vector according to  claim 1 , allowing the vector to replicate and shed virus, collecting the shed virus and purifying the collected virus.  
     
     
         21 . A method for generating an attenuated EHV which comprises modifying by molecular biology techniques the EHV sequence contained in an artificial chromosome vector according to  claim 1 .  
     
     
         22 . The method according to  claim 22  wherein a foreign sequence of another viral, bacterial or parasitic pathogen is added to the artificial chromosome vector.  
     
     
         23 . A method for generating a virulent EHV which comprises modifying by molecular biology techniques the EHV sequence contained in an artificial chromosome vector according to  claim 1 .  
     
     
         24 . The method according to  claim 23  wherein a foreign sequence of another viral, bacterial or parasitic pathogen is added to the artificial chromosome vector.

Join the waitlist — get patent alerts

Track US2003059934A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.